glucose, insulin, K+ (GIK)
Jump to navigation
Jump to search
Contraindications
Does NOT improve outcomes after acute myocardial infarction.
Patients without heart failure may benefit.[1]
Patients with heart failure may be harmed.
No benefit after thrombolysis in patient with STEMI[2]
- no benefit in subgroups (diabetes, heart failure)[2]
Dosage
- 8-12 hour IV infusion
More general terms
Components
References
- ↑ 1.0 1.1 Journal Watch 23(24):191, 2003 van der Horst ICC et al Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 42:784, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12957421 Apstein CS The benefits of glucose-insulin-potassium for acute myocardial infarction (and some concerns). J Am Coll Cardiol 42:792, 2003 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12957422
- ↑ 2.0 2.1 2.2 Journal Watch 25(5):38, 2005 Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L; CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005 Jan 26;293(4):437-46. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15671428